Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?
This article was originally published in The Pink Sheet Daily
Executive Summary
Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.
You may also be interested in...
Europe’s Pharma Industry Expects Little Relief In 2013 After Bruising 2012
Europe was a tough market for the drugs industry in 2012, with governments imposing austerity measures and price cuts on medicines that hit companies hard. The euro survived, preventing further disruption of the marketplace, but little respite is expected in the next 12 months for patients and companies alike from clampdowns on health care spending in general, and medicines reimbursement in particular.
Swedish Boost For Life Sciences Innovation Resonates Around Europe
Sweden’s government has allocated 4 billion kroner for the R&D sector and SEK 600 million specifically for life science in the hopes of rejuvenating Swedish R&D and getting the nation back on the top rankings of medicine innovation. It’s a theme being heard in other European countries.
Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs
The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.